inVentiv Clinical Trial Recruitment Solutions Shares Insights On The Use Of Behavioral Science To Improve Patient Recruitment And Retention Webinar May 22nd Discusses Advanced Techniques in Clinical Trial Patient Engagement
BURLINGTON, Mass., May 19, 2014 /PRNewswire/ -- inVentiv Clinical Trial Recruitment Solutions (iCTRS), created to efficiently and predictably accelerate trials, will host a webinar next Thursday for clinical trial sponsors on "Using Behavioral Science to Engage Clinical Trial Participants."
The one-hour webinar on May 22, 2014 begins at 1:30 p.m. EDT. Those interested in participating may register today on the website of Clinical Informatics News www.clinicalinformaticsnews.com/ecliniqua_webinar.aspx?id=137363.
The session, led by iCTRS Senior Vice President of Patient Recruitment Jim Kremidas and hosted by Clinical Informatics News, will explore how a science-based framework for communications planning can attract and retain patients for clinical research. Communication strategy emerges from deep insights into the processes people follow in making decisions, their motivational drivers and influencers who impact behavior.
"Behavioral research offers insights to help us develop messages that resonate with patients and motivate participation in a trial. What is more, effective messages keep patients deeply engaged with a study once enrolled," explains Kremidas. "The most progressive companies are taking advantage of empirical research techniques developed by behavioral and social scientists to improve patient engagement."
Participants will take away from the webinar a better understanding of:
- How to leverage behavioral sciences in patient engagement, recruitment and retention;
- How primary research can shed light on the patient journey;
- How patient insights can be applied to the best and most effective message development.
Following the webinar, all those registered will receive a link to an archived recording of the presentation to accommodate those who have a scheduling conflict. Additional information about iCTRS including news and events can be found by visiting www.inventivhealth-ictrs.com.
About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client's development and commercialization goals. With more than 12,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health's clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.
SOURCE inVentiv Health